hotspot -WSS

hotspot

author：hotspot 2025-09-01 05:57:41 - browse：143

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Contact tracing may help avoid another lockdown. Can it work in the U.S.?

leisure time

WSS

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Do more moles mean more problems? Not so, says new study

Health insurers say they are turning to AI to cut costs, improve care

Focused ultrasound for uterine fibroids: an uphill battle

Average age of first period drops to 11.9 years, study shows

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

White House launches permanent pandemic office

Heart attack and stroke risk calculators need revising

First Opinion Podcast: What happens when kids become caregivers?

Drug repurposing or repositioning? The language matters

Latest bird flu infection made farmworker sicker than earlier cases

Duchenne breakthrough therapy leaves behind pioneering families

Childbirth

Moonlake's readout produced a cash windfall. Risks remain

Startling documents reveal new facets of Sacklers' opioid empire

leisure time

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

New rules on organ donation and transplantation 'will bring chaos'

Heat waves linked to early deliveries, preterm births in new study

White House launches permanent pandemic office

Review: 'Barbie' will hit you like a shot in the heart

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

focus

leisure time

entertainment

focus